People living with HIV should be systematically screened
for active TB at each visit to a health facility.

Household contacts and other close contacts should be
systematically screened for active TB.

The Expert Group recommended that the Genotype MTBDRsl assay cannot be used as a replacement
test for conventional phenotypic DST.

Children living with HIV who do not have poor weight gain, fever or current cough are unlikely to
have active TB.

Providing IPT to people living with HIV does not increase the risk of developing isoniazid-resistant
TB. Therefore, concerns regarding the development of INH resistance should not be a barrier to
providing IPT.

Tuberculin skin test (TST) is not a requirement for initiating IPT in people living with HIV (strong
recommendation, moderate quality of evidence). People living with HIV who have a positive
TST benefit more from IPT; TST can be used where feasible to identify such individuals.

Adults and adolescents living with HIV who have an unknown or positive TST status and who are
unlikely to have active TB should receive at least 36 months of IPT. IPT should be given to such
individuals irrespective of the degree of immunosuppression, and also those on ART, those who
have previously been treated for TB and pregnant women.

Adults and adolescents who are living with HIV, have unknown or positive tuberculin skin test
(TST) status and are unlikely to have active TB should receive at least 6 months of IPT as part of
a comprehensive package of HIV care. IPT should be given to such individuals irrespective of the
degree of immunosuppression, and also to those on ART, those who have previously been treated
for TB and pregnant women.

Adults and adolescents living with HIV should be screened with a clinical algorithm; those who
do not report any one of the symptoms of current cough, fever, weight loss or night sweats are
unlikely to have active TB and should be offered IPT.

TB patients with known positive HIV status and TB patients living in HIV-prevalent settings should
receive at least 6 months of rifampicin treatment regimen (strong recommendation, high-quality
of evidence). The optimal dosing frequency is daily during the intensive and continuation phases.